miR‐221 confers lapatinib resistance by negatively regulating p27 kip1 in HER2‐positive breast cancer-Reference-Cited by-同舟云学术

miR‐221 confers lapatinib resistance by negatively regulating p27 kip1 in HER2‐positive breast cancer

Published:2021-08-27 Issue:10 Volume:112 Page:4234-4245
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Huynh Thanh Kieu¹²,Huang Chih‐Hao¹³,Chen Jhen‐Yu¹,Yao Jin‐Han⁴,Yang Yi‐Shiang²,Wei Ya‐Ling²,Chen Hsiao‐Fan²,Chen Chia‐Hung⁴⁵,Tu Chih‐Yen⁴⁵,Hsu Yuan‐Man⁶⁷,Liu Liang‐Chih³⁴,Huang Wei‐Chien¹²⁸⁹^ORCID

Affiliation:

1. Graduate Institute of Biomedical Sciences Drug Development Center China Medical University Taichung Taiwan

2. Center for Molecular Medicine China Medical University Hospital Taichung Taiwan

3. Division of Breast Surgery China Medical University Hospital Taichung Taiwan

4. School of Medicine China Medical University Taichung Taiwan

5. Division of Pulmonary and Critical Care Medicine Department of Internal Medicine China Medical University Hospital Taichung Taiwan

6. Department of Biological Science and Technology China Medical University Taichung Taiwan

7. Department of Animal Science and Technology Agriculture College Tunghai University Taichung Taiwan

8. The Ph.D. program for Cancer Biology and Drug Discovery China Medical University and Academia Sinica Taichung Taiwan

9. Department of Biotechnology Asia University Taichung Taiwan

Funder

China Medical University, Taiwan

China Medical University Hospital

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15107

Reference63 articles.

1. HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

2. The effects of the novel, reversible epidermal growth factor receptor/ErbB‐2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor‐derived cell lines in vitro and in vivo;Rusnak DW;Mol Cancer Ther,2001

3. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

4. Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

5. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges;Life Sciences;2024-07

2. miR-770-5p-induced cellular switch to sensitize trastuzumab resistant breast cancer cells targeting HER2/EGFR/IGF1R bidirectional crosstalk;Turkish Journal of Biology;2024-04-26

3. The predictive value of MiR-221 in cancer chemoresistance: a systematic review and meta-analysis;Expert Review of Anticancer Therapy;2023-06-05

4. HER2 induces cell scattering and invasion through ANp63? and E-cadherin;BIOCHEM CELL BIOL;2022

5. HER2 induces cell scattering and invasion through ∆Np63α and E-cadherin;Biochemistry and Cell Biology;2022-10-01